凯莱英 (002821)
Asymchem Laboratories (Tianjin) Co., Ltd.
K-Line Chart
No K-line data available
Company NameAsymchem Laboratories (Tianjin) Co., Ltd.
Listing Date2016-11-18
Issue Price30.53RMB
Registered Capital36059.37210k RMB
Legal RepresentativeHAO HONG
Registered AddressNo. 6, Dongting Third Street, Tianjin Economic-Technological Development Area
IndustryMedical Services
Main BusinessThe company's main business revenue can be categorized into two types by business segment: sales of goods and provision of services.
Company ProfileAsymchem Laboratories Group is a leading enterprise in China's pharmaceutical services industry. Founded in 1998 by Dr. Hao Hong in the Tianjin Economic-Technological Development Area, the company is dedicated to technological innovation and commercial application in global pharmaceutical processes. It provides one-stop drug R&D and production services to pharmaceutical companies, including the world's top ten pharmaceutical corporations. Over the years, the company has established six subsidiaries in China, holds over 60 invention patents, and has successfully secured numerous national and provincial/municipal projects such as the National Major New Drug Creation Program, the National 863 Program, Tianjin's 'Mayor's Fund' Project, Tianjin's Independent Innovation Industrialization Project, and Tianjin's Major High-Tech Industrialization Project. It has also been awarded the 'Primary Supplier Award' by Merck, the 'Best Intermediate Contract Manufacturer Award' by Pfizer, and the 'Most Valuable Partner' award by Roche.
Stock Details
1. Key Indicators
- Total Shares(W): 36059.37
- Circulating A-Shares(W): 31699.99
- Earnings Per Share(RMB): 2.1800
- Net Assets Per Share(RMB): 48.1160
- Operating Revenue(W RMB): 462987.71
- Total Profit(W RMB): 90994.91
- Net Profit Attributable to Parent(W RMB): 80024.52
- Net Profit Growth Rate(%): 12.66
- Weighted Return on Equity(%): 4.63
- Operating Cash Flow Per Share(RMB): 3.1730
- Undistributed Profit Per Share(RMB): 23.5256
- Capital Reserve Per Share(RMB): 24.1053
2. Main Business
The main business covers:
- Providing a full life-cycle one-stop service for domestic and foreign pharmaceutical companies and biotechnology companies.
3. Company Basic Information
- Company Name: Asymchem Laboratories (Tianjin) Co., Ltd.
- Listing Date: 2016-11-18
- Industry: Pharmaceutical Manufacturing
- Address: No. 71, 7th Avenue, Tianjin Economic-Technological Development Area, Tianjin, China
- Website: www.asymchem.com.cn
- Company Profile: The company was established through the overall change of Asymchem Laboratories (Tianjin) Co., Ltd. It provides a full life-cycle one-stop service for domestic and foreign pharmaceutical companies and biotechnology companies.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | ASYMCHEM LABORATORIES, INCORPORATED | General Legal Person | 11513.32 | 36.32 |
| 2 | China Europe Healthcare Hybrid Securities Investment Fund A | Fund | 1631.90 | 5.15 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 1328.77 | 4.19 |
| 4 | Tianjin Guorong Business Information Consulting Co., Ltd. | General Legal Person | 637.66 | 2.01 |
| 5 | Huabao CSI Healthcare ETF | Fund | 564.67 | 1.78 |
| 6 | China Europe Healthcare Innovation Equity Securities Investment Fund A | Fund | 487.80 | 1.54 |
| 7 | Asymchem Laboratories (Tianjin) Co., Ltd. - 2022 Employee Stock Ownership Plan | General Legal Person | 318.28 | 1.00 |
| 8 | China Merchants CSI Bio-medicine Index Securities Investment Fund (LOF) A | Fund | 293.60 | 0.93 |
| 9 | Tianhong Pharmaceutical Innovation Hybrid Securities Investment Fund A | Fund | 90.28 | 0.28 |
| 10 | China Merchants Healthcare Industry Equity Securities Investment Fund | Fund | 70.53 | 0.22 |
5. Concept Sectors
- H-Share
- CXO Concept
- Innovative Drug
- Weight Loss Drug
- Synthetic Biology
- Margin Trading & Securities Lending
- High-Performance Stock
- Fund Heavy Holdings
- MSCI Mid Cap
- Overseas Business
- Fund Reducing Holdings
- Non-Cyclical Stock
- SME 100
- Mid Cap Growth
- SZSE 300
- Technology 100
- SZSE Growth
- SME 300
- SZSE Innovation
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information
